GX-BP1 / Genexine - LARVOL DELTA

Genexine, Non-small cell lung cancer new drug development 'GX-BP1' key technology international patent [Google translation] (Medipana) - "Genexine...announced on the 26th that it has completed an international patent PCT (Patent Cooperation Treaty) application for the key technology included in GX-BP1, which is being developed as a treatment for non-small cell lung cancer....The patent in question is an international patent for 'a single-domain antibody specifically binding to SOX2, a fusion protein comprising the same, and uses thereof' and includes a nanobody showing excellent binding affinity to SOX2 and an E3 ligase material optimized for SOX2 degradation."

Patent • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Genexine Shares Results of Lung Cancer...at US TPD Summit [Google translation] (HIT News) - "In this presentation, Vice President Choi disclosed key in vitro results of the bioprotactic pipeline GX-BP1 targeting the SOX2 protein, and shared the in vivo experimental results that demonstrated tumor growth inhibition and high degradation efficacy against intratumoral SOX2 protein in a xenograft animal model."

Preclinical • Lung Cancer • Oncology • Solid Tumor

Genexine, EPD Bio merger… “Bioprotac new drug development begins in earnest” [Google translation] (Medipana) - "Genexine...announced on the 2nd that it has completed its merger with EPD Biotherapeutics Inc. The company decided to merge with EPD Bio at a board meeting held on June 26th, and signed a merger agreement on July 1st. The merger new stock listing date is scheduled for October 17th...Through this merger, Genexine will acquire EPDeg, a bioPROTAC platform technology that can overcome the limitations of PROTAC...a representative technology in the TPD field, as well as innovative new pipelines and EPD Bio’s key research personnel with many years of industry experience...The pipeline that will enter the clinical stage the fastest is GX-BP1 (SOX2 bioPROTAC) targeting 'SOX2', a cancer-causing transcription factor...Genexine is proceeding with preclinical sample production this year and aims to apply for a domestic phase 1 clinical trial plan (IND) by the end of next year based on the animal testing results...In addition, Genexine is developing GX-BP2..."

M&A • New P1 trial • Atopic Dermatitis • Immunology • Lung Cancer • Oncology • Solid Tumor